Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and its prevalence
increases with age. Few data are available about the clinical performance of direct oral …

Direct oral anticoagulants (DOACs) have shown similar efficacy and safety with respect to
warfarin in patients with atrial fibrillation (AF). However, the proportion of patients aged≥ 85 …

Older people, are underrepresented in randomised controlled trials of direct oral
anticoagulants (DOACs) for stroke prevention in atrial fibrillation (AF). The aim of this study …

BACKGROUND: Concerns regarding the use of direct oral anticoagulants (DOACs:
apixaban, dabigatran, edoxaban, rivaroxaban) in the elderly persist owing to the lack of …

Atrial fibrillation is the most common arrhythmia in clinical practice, and age is one of the
strongest predictors/risk factors for ischemic stroke in patients with atrial fibrillation. Elderly …

Objectives Nonagenarian patients are underrepresented in clinical trials that have evaluated
oral anticoagulation in patients with atrial fibrillation (AF). The aim of this study was to assess …

Abstract Direct Oral Anticoagulants (DOACs) consistently demonstrated a greater net clinical
benefit compared to Vitamin K Antagonists (VKAs) also in persons aged 75 years and over …

Background Patients aged 90 years or older are often excluded from or under-represented
in clinical trials and cohort studies. The clinical benefit of anticoagulation in nonagenarians …

Abstract Introduction Direct oral anticoagulants (DOACs) are underused in the elderly,
regardless the evidence in their favour in this population. Methods We prospectively …

Direct oral anticoagulants (DOACs) have been demonstrated to be more effective and safer
than vitamin-K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial …